UIC
LGND icon

Uniplan Investment Counsel’s Ligand Pharmaceuticals LGND Stock Holding History

Uniplan Investment Counsel’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Sell
34,249
-5,936
-15% -$1.4M 1.02% 22
2026
Q1 		$8.02M Sell
40,185
-2,179
-5% -$431K 0.82% 29
2025
Q4 		$8.01M Buy
42,364
+188
+0.4% +$36.1K 0.8% 31
2025
Q3 		$7.47M Sell
42,176
-20,777
-33% -$3.09M 0.73% 35
2025
Q2 		$7.16M Sell
62,953
-5,839
-8% -$624K 0.72% 38
2025
Q1 		$7.23M Buy
68,792
+637
+0.9% +$72K 0.7% 37
2024
Q4 		$7.3M Buy
68,155
+15,051
+28% +$1.7M 0.68% 39
2024
Q3 		$5.32M Buy
53,104
+3,487
+7% +$351K 0.46% 54
2024
Q2 		$4.18M Buy
49,617
+8,416
+20% +$670K 0.38% 65
2024
Q1 		$3.01M Buy
+41,201
New +$3.04M 0.24% 84

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Uniplan Investment Counsel's LGND Position: Q2 2026 in Review

Uniplan Investment Counsel reduced its Ligand Pharmaceuticals (LGND) stake by 15% in Q2 2026, selling an estimated $1.4M and leaving 34,249 shares worth $10.8M. The position accounts for 1.02% of the portfolio, ranked #22.

Uniplan Investment Counsel first reported a position in LGND in Q1 2024 and has held it in 10 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Uniplan Investment Counsel held 34,249 shares of Ligand Pharmaceuticals worth $10.8M as of Q2 2026.
  • Uniplan Investment Counsel sold 5,936 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.4M.
  • Ligand Pharmaceuticals made up 1.02% of Uniplan Investment Counsel's portfolio in Q2 2026, its #22 holding.
  • Uniplan Investment Counsel first reported a position in Ligand Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Uniplan Investment Counsel's 13F filing for Q2 2026, filed 13 Aug 2026.